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ABSTRACT 
 
 
 Ependymin (EPN) is a goldfish brain neurotrophic factor (NTF) previously shown 
to function in a variety of cellular events related to long-term memory formation and 
neuronal regeneration.  Because of these functions, EPN and other NTFs have potential 
applications for treating neuro-degenerative conditions, including stroke.  In previous 
experiments, our lab in collaboration with Victor Shashoua of Ceremedix Inc (Boston, 
MA), designed short synthetic peptide CMX-8933 (a proteolytic cleavage product of 
EPN) and CMX-9236 (an EPN-Calmodulin combination peptide) that mimic the action 
of full-length EPN.  In a rat stroke model, administration of these peptides i.v. 
significantly lowered brain ischemic volume (Shashoua et al., 2003).  Because oxidative 
stress is one of the primary mediators of cell damage following a stroke, we hypothesized 
that NTFs, and in particular our therapeutic peptides, may act in part by reducing 
neuronal oxidative stress.  Thus, the purpose of this thesis was to determine whether 
CMX-8933 and CMX-9236 increase the cellular titers of anti-oxidative enzymes.   
 A hybridization array was used as a “hypothesis generator” to obtain candidates 
for further analysis.  This approach applied to rat primary brain cortical cells treated with 
CMX-8933 identified superoxide dismutase (SOD) as strongly upregulated.  SOD 
immunoblots on whole cell lysates, and RT-PCR on total cellular RNA, were used to 
confirm this observation.  In time-course and dose-response experiments, treatment of rat 
primary cortical cultures with either peptide showed an optimal 8.5 fold (N = 5, p < 
0.001) increase in SOD protein, while administration of CMX-8933 to murine 
neuroblastoma cells caused a 6.5 fold (N = 3, p = 0.001) increase in SOD mRNA levels.  
 Previous work in other laboratories indicated that systemic (i.v.) administration of 
full-length NTFs allows only an inefficient delivery across the blood brain barrier (BBB).   
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We hypothesized that our short synthetic peptides may cross the BBB more efficiently.  
Immunoblot analysis of brains and hearts excised from mice treated i.v. with various 
doses of CMX-8933 confirmed the elevated SOD titers (10 fold in brain, and 8 fold in 
heart, at a 6 mg/kg dose for 5 hr; N = 5, p < 0.001).   Furthermore, we hypothesized that 
conjugation of CMX-8933 to BBB carrier DHA, a natural neuronal membrane fatty acid 
shown previously to enhance the delivery of dopamine to the brain (Shashoua and Hesse, 
1996), might further enhance the NTF therapy.   Delivery of DHA-8933 increased SOD 
expression by 3 fold (N = 4, p < 0.001) relative to non-conjugated CMX-8933.  
 Recently, the use of special incubators that allow the culture of cells under low 
oxygen conditions (anoxia) has been used as an in vitro model for stroke.  When we 
tested our peptides in this new in vitro model, surprisingly SOD was upregulated 3 fold 
(N = 3, p = 0.003) in rat primary cortical cells cultured for 24 hr under oxygen 
deprivation, compared to normoxic conditions.  This implies that these rat cultures may 
have an endogenous cellular system for responding to oxygen stress, a finding worthy of 
further investigation.  Treatment of anoxic cells with CMX-8933 increased SOD levels 
another 2.8 fold (N = 3, p < 0.001) compared to the levels for anoxia alone (for a total of 
8.5 fold relative to normoxic cells).  Altogether, the data from this thesis illustrate that 
small NTF EPN peptide mimetics increase the cellular titers of the mRNA and protein for 
the anti-oxidative enzyme SOD, which may be an important step in their known 
therapeutic benefits. 
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BACKGROUND 
 
 
Neurotrophic Factors 
 Neurotrophic factors (NTFs) are naturally occurring proteins that promote and 
control the development, survival, and maintenance of neuronal and glial cells (Abe, 
2000).  NTFs play a key role in the development of both the central and peripheral 
nervous system (Ikeda et al., 2000).  Because of the ability of some NTFs to regenerate 
brain tissue, they are implicated to have potential restorative effects in neurodegenerative 
disorders such as Parkinson’s disease, Alzheimer’s disease and stroke. 
  
Role of NTFs in Stroke Therapy  
NTFs help assuage the destructive neuronal oxidative stress associated with 
stroke.  Apoptotic-like cells predominate for several days after an ischemic insult in the 
internal region of the borders of the infarct, the so-called penumbra zone (Linnik et al., 
1995). Several NTFs like nerve growth factor (NGF), brain-derived neurotrophic factor 
(BDNF), glial-derived neurotrophic factor (GDNF), Neurotrophin-3 etc. have been found 
to localize in the penumbra following a stroke (Ferrer et al., 1998) presumably to aid 
neuronal recovery.  Because of this, some NTFs have been tested as stroke therapeutics.  
Intracerebrally delivered BDNF is effective in reducing infarction volume, hippocampal 
cell damage and death, and cortical neuron death (Ferrer et al., 2001).  BDNF therapy 
also prevents superoxide anion-induced death in cells expressing the Trk B Tyrosine 
kinase receptor, a receptor that mediates neurotrophin signaling (Yamagata et al., 1999). 
Studies show that GDNF alleviates oxidative stress in neurons by blocking nitric oxide, 
and/or scavenging free radicals that are produced from ischemia (Ikeda et al., 2000).   
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Ependymin 
Ependymin (EPN) is a goldfish brain glycoprotein found predominantly in the 
brain extracellular fluid (ECF) and cerebrospinal fluid (CSF) in glycosylated and non 
glycosylated forms.  Discovered in 1976 by Victor Shashoua (formerly of Harvard 
Medical School, McLean’s Hospital, currently of CereMedix Inc.), EPN was identified as 
a protein whose turnover rate was enhanced in goldfish brains after various training 
events.  Isolation and localization studies indicate that EPNs are synthesized in the zona 
ependyma of the goldfish brain (Shashoua and Benowitz, 1977) and in the meninges of 
goldfish and zebrafish brains (Hoffmann et al., 1990).  
 
Ependymin Functions as a Neurotrophic Factor 
Although the precise molecular mechanism by which the brain uses EPN remains 
unknown, there are certain functional aspects of EPN that closely resemble the properties 
of NTFs.  Surprisingly addition of goldfish EPN to murine neuroblastoma NB2a cell 
cultures enhances neurite sprouting and extension (Shashoua et al., 1992); a phenomenon 
also observed with NGF (Conner and Varon, 1995) and BDNF (Patel and McNamara, 
1995).  So although EPN was originally discovered in goldfish, it may have mammalian 
counterparts. 
Three behavioral experiments (swimming with a float, avoidance conditioning, 
and classical conditioning) in the goldfish indicate that EPN has a role in the synaptic 
changes associated with the consolidation process of long-term memory formation and 
the activity-dependant phase of the sharpening of goldfish retinotectal connections during 
neuronal regeneration (Shashoua, 1991).  When given anti-EPN antisera prior to an optic 
nerve crush, retinotectal projection was blocked in goldfish (Schmidt and Shashoua, 
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1988).  Similarly, an antiserum to EPN when injected into the brains of trained goldfish 
caused amnesia of a newly acquired behavior (Shashoua and Moore, 1978).  A multi-
functional protein, EPN was recently found to increase goldfish acclimation to cold 
temperatures (Tang et al., 1999).  EPN also has a characteristic calcium-binding affinity 
comparable to the ubiquitous calcium-chelator Calmodulin (Schmidt and Makiola, 1991), 
which perhaps allows EPN to be used for stroke therapy helping to chelate calcium 
before it floods into a damaged cell.  In addition, EPN is expected to show the signal 
transduction-induced changes in gene expression associated with all NTFs. 
 
Our Lab’s Contribution Towards EPN 
The Adams lab, in collaboration with CereMedix, Inc. (Boston), has contributed 
significantly towards EPN research.  The earliest work involved the discovery, cloning 
and characterization of genes encoding EPN in goldfish and carp (Adams and Shashoua, 
1994), and in giant danio and golden shiner (Adams et al., 1996).  Research using NTF-
EPN peptide mimetics 8933 and 9236 (discussed below) began in 1998, when a Master’s 
student (Hasson, 1998) showed that these therapy peptides stimulate the transcription 
factor activator protein (AP-1), a signaling molecule that turns on neuronal growth genes.  
This AP-1 activated by 8933 and 9236 was later proved to be functional in neuroblastoma 
NB2a cells using transfection experiments (El-Khishin, 1999).  In the same year mouse 
C-127 cells were engineered to secrete peptides CMX-8933 or 9236 into the culture 
medium in an attempt to develop a cost effective cell culture-based in vitro production 
system for these peptides (Sleeper, 1999).  In 2001, therapy peptide CMX-8933, a 
proteolytic cleavage product of EPN, was shown to activate AP-1 in mouse 
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neuroblastoma and rat cortical cultures (Adams et al., 2001), thus extending and 
combining the earlier student projects.  Further investigations showed that 8933 activates  
AP-1 using the MAPK pathway (Adams et al., 2003).  The activation of AP-1 by EPN 
mimetic 8933 appears to be significant since AP-1 was recently shown to be a master 
switch that functions upstream of all other transcription factors to control long term 
memory formation and synaptic plasticity (Sanyal et al., 2002) which are two processes 
that also describe EPN’s function.  The most recent work in our lab involves an analysis 
of the neuroprotective effects of the therapy peptide CMX-9236 in in vitro and in vivo 
models of cerebral ischemia (Shashoua et al., 2003), and this work is discussed below. 
 
EPN Peptide Therapy 
 Because full-length NTFs cross the BBB inefficiently, even when coupled to a 
BBB-carrier, CereMedix, Inc. designed two short NTF-EPN peptide mimetics CMX-
8933 (MW 1049 Da) and CMX-9236 (MW 1477 Da) as potential therapies.  These short 
specific peptide sequences were selected in preference to the complete EPN molecule to 
avoid any possible contamination with NGF, a normal component of the ECF of goldfish 
from which EPN is isolated (Adams et al., 2001).  
 CMX-8933 is an 8 amino acid synthetic peptide whose sequence is directly 
derived from a charged region of EPN with a conserved sequence of “KKETLQFR” (fig. 
1, red letters).  The two N-terminal lysine residues (KK) were included to enhance the 
peptide’s water solubility (Adams et al., 2003).  This sequence is completely conserved 
among all the protein sequences derived from true-EPN genes sequenced to date from the 
order Cypriniformes, the only order in which functional EPN studies have been 
performed (Adams and Shashoua, 1994; Adams et al., 1996; Adams et al., 2003).  CMX-
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8933 activates AP-1 in a manner similar to the full-sized NTFs, NGF and BDNF, 
suggesting a parallel mechanism in neuronal protection (Adams et al., 2001).  ECF 
proteins from goldfish brains contain proteases and the peptide equivalent of synthetic 
8933 (Shashoua and Holmquist, 1986).  The 8933 sequence is also flanked by known 
protease cleavage sites (Adams et al., 1996).  Thus peptide CMX-8933 is believed to 
represent a proteolytic cleavage product of EPN in the ECF (Adams et al., 2003) and 
hence is likely to be biologically relevant. 
 
   Goldfish EPN sequence 
        +      +                                                 +     +          +                       +                         + -    -      -        -    +       +   +     - - 
    MHTVKLLCVVFS-CLCAVAWAS--SH---R-QPCHAPPLTSGTMKVVST------GGHDLESGEFSYDSKANKFRFVED 
          +      +      +     -        +   - -            -  -     +   -      + + -          + + +      -       -       + -   -                      -         +    +      +  
    TAHANKTSHM-DVLIHFEEGVLYEIDSKNESCKKETLQFRKHLMEIPPDATHESEIYMGSPSITEQGLRVRVGKFP    
     -   +   +                                             +   - + + -     +               -    -    - -                             -       - -      - -   +           -      +  -      
    ELHAHYSMSTTSCGCLPVSGSYHGEKKD-LHFSFFGVETEVDD-LQVFVPPAYCEGFEEAPDDHS—FFDLFH-D          215aa 
 
Fig 1.  Rationale for the Design of Therapy Peptide CMX-8933.  The completely conserved 8 amino 
acid sequence of CMX-8933, represented in red, is a proteolytic cleavage product of a 215 aa long Goldfish 
EPN, present in ECF.  Charged amino acids are indicated by ‘+’ or ‘-’ above the sequence (Adams et al., 
1995; Adams et al., 2003). 
  
 
CMX-9236 is a 14 amino acid synthetic peptide derived in part from the sequence 
of EPN and the sequence of one of the calcium binding domains of calmodulin with a 
consensus sequence of “KKDGDGDFAIDAPE” (fig 2; Shashoua et al., 2003).  The 
peptide was designed as a single molecule with properties that combined an affinity for 
calcium along with a capacity to activate AP-1 and thus promote synaptic plasticity.  Its 
N-terminal end is usually coupled to a fatty acid, cis-docosahexanoic acid (DHA) to 
allow penetration across the blood-brain barrier (discussed in detail below). 
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             Fig 2. Structure of Peptide CMX-9236. It contains 6 calcium-binding sites, indicated by the    
             arrows that are considered to be involved in calcium chelation (Shashoua et al., 2003). 
 
 
In neurotrophic activity studies, both EPN peptides CMX-9236 and CMX-8933 
were found to prevent the death of rat primary hippocampal neurons treated with 
excitotoxic levels (2 mM) of glutamate (figs 3 and 4; Shashoua, unpublished). 
                                                                                                                                                                 
 
Fig 3. CMX-9236 Blocks Cell Death from Glutamate Excitotoxicity.  Rat cortical cultures  
preincubated with excitotoxic levels of glutamate for 60 min showed a 5 fold increase in the  
number of dead cells/field relative to the same cultures post-treated with CMX-9236 for 15, 30,  
45, or 60 min.  Stain used was propidium iodide, which is an indicator of dead cells (Adapted from 
Shashoua, unpublished). 
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              Fig 4. Effects of CMX-8933 on Neuronal Cell Survival in vitro. Legend is as described 
      for fig. 3, except Y-axis shows percent viable cells (Shashoua, unpublished). 
 
Increased accumulation of intracellular calcium following an ischemic insult 
initiates a cascade of biochemical changes that ultimately leads to cell necrosis and 
apoptosis.  A fluoroprobe assay demonstrated the efficacy of CMX-9236 in restoring the 
increased intracellular calcium resulting from kainate (an excitotoxic glutamate analog) 
excitotoxicity back to normal (fig. 5, Shashoua et al., 2003).    
 
 
 
 
 
 
 
Fig 5. Calcium Chelating Capacity of CMX-9236 after Treatment with Excitotoxic Levels of Kainic 
Acid.  Rat primary cortical cultures were preloaded with Fluo-3, a dye that fluoresces on binding to 
calcium.  Panel A is the saline control.  Panel B shows the treatment with 100 µM excitotoxic kainate 
indicating intense fluorescence due to increased intracellular calcium.  Panel C represents the continuous 
infusion of 50 ng/ml of CMX-9236 to kainate treated cultures resulting in decreased fluorescence to about 
pre-stimulation stage within 5 minutes (Shashoua et al., 2003). 
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 In perhaps the most significant in vivo studies performed to date by the Adams 
and Shashoua labs, CMX-9236 and CMX-8933, in a rat stroke model, induced a dramatic 
reduction of infarct size following a 24 hour major occlusion of the middle cerebral artery 
(figs. 6 and 7; Shashoua et al., 2003; Shashoua, unpublished). 
 
           
                Control                       CMX-9236 
 
Fig 6. CMX-9236 Decreases the Size of Brain Infarct in a Rat Model for Stroke.  The figure shows 
serial coronal brain sections (rostral to caudal) dissected from permanent MCA occlusion rat stroke models.  
Surviving tissue stains red with TPT (2, 3, 5-Triphenyltetrazolium) dye, while the dead cells remain white.  
The CMX-9236 treated brain (right) shows a substantial reduction in infarct size compared to the control 
brain (left) (Shashoua et al., 2003). 
 
            
CMX-8933 Dose mg/hr 
 
       Fig 7. Effect of CMX-8933 on Infarct Size in a Rat Model for Stroke.  CMX-8933 
                     significantly reduces the size of brain infarct in comparison to the untreated brain (left)  
       in the permanent (24 hr) occlusion stroke model (Shashoua, unpublished). 
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DHA-BBB Carrier 
 Neuroprotection following the systemic administration of full-length NTFs is 
generally not possible because these proteins are unable to cross the tight endothelial 
junctions lining the blood-brain barrier.  Even the short synthetic peptides 8933 and 9236 
cross the BBB inefficiently.  One approach to the BBB problem is to couple the amino-
terminal ends of these synthesized EPN peptides with cis-docosahexanoic acid (DHA), a 
lipid-soluble carrier molecule.  DHA is a major fatty acid component of synaptic endings 
(Sun and Yau, 1976).  Its lipophilic properties assist the diffusion of linked molecules 
across cell membranes, allowing the delivery of therapeutic molecules (like dopamine) 
into the brain (Shashoua and Hesse, 1996).  Moreover DHA is essential for post-natal 
brain development, synaptogenesis, and photoreceptor membrane formation and function 
(Shashoua and Hesse, 1996) making it an attractive natural carrier. 
Protarga, Inc. (Conshohocken, Pennsylvania) is a pharmaceutical company, 
founded by Dr. Shashoua, that makes use of this DHA-BBB carrier system to develop 
Targaceutical® compounds.  Its targaceutical technology uses fatty acids as vectors to 
deliver more drug to targeted cells and achieve a sustained release of the therapeutic 
agent (Potera, 2001).  The company’s three lead drugs: Taxoprexin®, Doprexin® and 
Clozaprexin® are currently undergoing clinical trials. Taxoprexin®, a DHA-paclitaxel 
compound, which is an innovative new treatment for cancer, has recently proceeded to 
Phase III clinical trials (Protarga Homepage, 2003).  Doprexin®, a DHA-Dopamine 
compound has applications for Parkinson’s disease.  Coupling DHA to dopamine 
increased brain uptake of dopamine by over 10-fold (Shashoua and Hesse, 1996).  
Clozaprexin®, made by coupling the potent anti-psychotic drug clozapine to DHA, is 
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used to treat psychotic disorders like schizophrenia.  Studies show that clozaprexin is 10 
times more potent and longer lasting than clozapine alone (Baldessarini et al., 2001). 
 
Mechanism of Action of EPN-NTF Peptides 
 The precise mechanisms by which EPN peptides exert their neuroprotective 
actions in vivo are presently unknown.  Work in progress in our lab is directed towards 
this goal.  However, accumulating evidence suggests a biological mechanism, wherein 
the full length EPN, or the proteolytic cleavage products of EPN present in the ECF, may 
bind to a high affinity putative EPN receptor, initiating a signal transduction cascade 
involving series of biochemical steps (fig. 8, right side).  The enzyme c-Jun-N-terminal 
kinase (JNK), a member of the MAP kinase family activated by 8933 (Adams et al., 
2003), phosphorylates AP-1 leading to its activation and translocation to the nucleus.  
Activation of AP-1 could be a prerequisite for repair of brain injury, such as synaptic 
uncoupling that frequently occurs following an ischemic event.  Previous studies in a 
number of laboratories have demonstrated an active role for AP-1 activating genes that 
promote cell proliferation, differentiation and survival mechanisms (summarized in 
Adams et al., 2001). 
Alternatively, EPN peptides may also have an intracellular function (fig. 8, left 
side).  Peptides coupled to the lipophilic DHA carrier may pass directly through the 
neuronal membrane into the cytoplasm.  The DHA carrier is then cleaved by the normal 
cellular enzymes (Shashoua and Hesse, 1996) releasing the original peptide into the 
cytoplasm.  The peptide then chelates increased intracellular calcium bringing the 
calcium levels to normal.  DHA-8933 and uncoupled 8933 each activate AP-1, so the 
coupling of 8933 to the carrier does not appear to disrupt its receptor-binding properties. 
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Fig 8. Working Hypothesis for NTF-EPN Peptide Mimetics.  2 pathways have been implicated in the 
peptide’s neuroprotective effects.  The biological pathway represented by ‘1’ (right side) involves a signal 
transduction cascade leading to AP-1 upregulation via a putative ependymin receptor.  The therapeutic 
unnatural (DHA) pathway represented by ‘2’ (left side and right side) involves both the direct delivery of 
the DHA peptide across the neuronal cell membrane (left side) where it chelates intracellular calcium, as 
well as AP-1 activation triggered by ligand-receptor binding.    
 
 
 
 
Anti-Oxidative Enzyme SOD 
 It is well known that toxic reactive species are overproduced in biological 
organisms following CNS injury, causing oxidation of cellular components.  An 
increased production of superoxide radicals leading to oxidative stress is seen in neurons 
shortly after ischemic injury (Kim et al., 2002).  Under normal physiological conditions, 
damage by superoxide radicals is kept in check by an efficient antioxidant system, which 
involves the production of free-radical scavengers like Superoxide dismutase (SOD), 
Catalase and Glutathione Peroxidase (GPX).  
 SOD is an endogenous anti-oxidative enzyme that catalyzes the dismutation of 2 
superoxide anions to hydrogen peroxide, which is then broken down by Catalase or GPX 
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to water and molecular oxygen (Sun and Chen, 1998).  Several investigators have 
reported that transgenic mice over-expressing SOD are resistant to injury that occurs 
during reperfusion following transient focal cerebral ischemia, as measured by smaller 
infarct size (Kinouchi et al., 1991; Chan et al., 1993; Yang et al., 1994).  A variety of 
studies have revealed that transgenics over-expressing SOD appear to build resistance to 
cerebral ischemia (Chan et al., 1998; Sheng et al., 1999; Li et al., 2001).  Moreover 
neuronal over-expression of SOD also plays a protective role in Parkinson’s and 
Alzheimer’s disease.  Conversely, targeted disruption of the CuZn-SOD coding sequence 
causes increased edema and enlarged infarcts after murine middle cerebral artery 
occlusion (Sheng et al., 1999).  An interesting finding by Araki et al (1992) suggested 
that the histoprotective action of SOD might also be due to its ability to attenuate the 
increase in intracellular calcium following stroke.    
 It is commonly known that the level of cellular oxidative stress increases with 
age and is a major causal factor in senescence.  SOD has been implicated to have a 
potential role in deterring the aging process.  Studies done in Drosophila melanogaster 
indicate a dramatic extension of Drosophila lifespan when the fly motor neurons were 
engineered to over-express human SOD-1 (Parkes et al., 1998).  Similar studies done by 
Kitani et al (1996) suggested that neuronal over-expression of SOD and Catalase plays a 
major role in lengthening the mammalian life span.       
  
Anoxia 
 Anoxia, a decreased oxygen condition commonly termed ischemic 
preconditioning, has emerged as a new topic in stroke therapy.  Brief ‘preconditioning’ 
ischemia induces ischemic tolerance and protects the animal brain from subsequent 
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otherwise lethal ischemia.  A cascade of signaling events initiated by sublethal stress 
proceeds during the latent period, resulting in a new, stress-resistant, biochemical makeup 
of brain cells (Liu et al., 2000). 
 Anoxia is produced in vitro in a cell culture environment consisting mostly of 
nitrogen, hydrogen and carbon dioxide for a short period of time, followed by 
reoxygenation (Jourdain, 2002).  Studies show that after exposure to an anoxic 
environment, SOD and catalase levels in turtles dramatically increased, suggesting an 
anti-oxidant system was signaled (Willmore and Storey, 1997).  Anoxia also resulted in 
an increase in the activities of brain GPX in goldfish by 79%, and after 14 hours of 
reoxygenation, brain GPX activities remained higher than control (Lushchak et al., 
2000).  An overall 30% reduction in infarct volume was seen when ischemic injury was 
introduced to anoxic preconditioned mice (Bernaudin et al., 2002).  Tolerance was seen 
against focal transient and permanent cerebral ischemia in adult mice (Bernaudin et al., 
2002). 
  The mechanism of ischemic preconditioning is unknown.  Using anoxia-tolerant 
turtle as a model, the activity of the mitogen activated kinase family was analyzed in 
organs exposed to anoxia in vivo.  The anoxic brain showed a 2 fold increase in the level 
of transcription factor c-Fos and increased JNK activity (Greenway and Storey, 2000) 
suggesting a possible role in the MAPK pathway mediating the adaptive response to 
oxygen deprivation.  Alternately, Bernaudin et al (2002) suggested that expression of 
Hypoxia-inducible factor (HIF-1) along with its target genes erythropoietin and vascular 
endothelial growth factor (VEGF) could be important mediators of hypoxia-induced 
tolerance to cerebral ischemia. 
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THESIS PURPOSE 
 
 
The purpose of this project was to test a three-part hypothesis.  As mentioned 
earlier, CereMedix Inc. synthesizes small size Ependymin (EPN) peptide mimetics CMX-
8933 and CMX-9236 that alleviate ischemic damage.  It is well established that increases 
in oxidative stress result from ischemia, so we have hypothesized that our therapeutic 
peptide may alleviate oxidative stress.  The primary goals of this project were to 1) 
determine whether CMX-8933 and CMX-9236 increase the cellular titers of the mRNA 
and protein for the anti-oxidative enzyme SOD.  SOD was identified as a likely candidate 
for analysis based on early experiments in this thesis with hybridization arrays.  2) Since 
our previous studies indicated that DHA facilitates movement of dopamine across the 
blood brain barrier (Shashoua and Hesse, 1996), I wanted to test if conjugation of peptide 
CMX- 8933 to a DHA-BBB carrier further increases the expression of SOD.  3) Anoxia 
is a newly established in vitro system for studying stroke which uses a low oxygen cell 
culture environment to mimic in vivo ischemia.  The third goal was to examine whether 
anti-oxidative events, specifically the upregulation of SOD, are a part of the cell’s natural 
response to anoxia, and to determine whether anoxic neuroblastoma cells, when 
stimulated with peptide 8933 increase SOD levels beyond anoxic levels.   
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MATERIALS AND METHODS 
 
 
 
Murine Neuroblastoma Cell Culture 
 The murine Nb2a neuroblastoma cell line (Neuro-2A) was purchased frozen from 
American Type Culture Collection (ATCC), Catalog # CCL-131 and thawed by rapid 
(~40-60 sec) agitation in a 37°C water bath.  Other cell culture products, Dulbecco's 
Modified Eagle's medium (DMEM; with glutamine and sodium pyruvate), Trypsin-
EDTA solution (0.25% Trypsin; 1 mM EDTA), Fetal Bovine Serum (FBS), MEM Non-
Essential Amino Acids Solution (100X, 10 mM) and Gentamycin (10 mg/ml) were 
purchased from Life Technologies, Inc. 
 
Complete Medium Preparation 
 500 ml of DMEM culture medium was supplemented with 5 ml of Non-essential 
amino acids (0.1 mM), 50 ml of 10% FBS and 250 µl of gentamicin (5 ug/ml) to make 
complete culture medium.  The contents were mixed briefly and then filtered aseptically 
through a pre-sterilized filter using a vacuum pump. 
 
Subculturing 
  Thawed NB2a cells were transferred to a vented T-25 culture flask and diluted 
with 10 ml of the complete medium.  Flasks were incubated at 37°C in a humidified 
atmosphere containing 5% CO2.  When the cells attained confluency, the medium was 
removed, the monolayer was washed with old DMEM medium and the wash solution was 
discarded.  The cells were then incubated with 2 ml of Trypsin-EDTA solution at 37°C 
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for 2 minutes with periodic, gentle agitation until the monolayer detached from the flask 
surface.  The cell suspension was then flooded with an equal volume of complete DMEM 
to stop trypsinization, transferred to a 15 ml conical tube, and centrifuged (25°C, 5 min, 
500 x g).  Trypsin-containing medium was removed from the cell pellet, and cells were 
resuspended in fresh pre-warmed DMEM.  The cells were then split and appropriate 
aliquots were dispensed into new flasks at 1:3 or 1:6 dilutions.   Medium renewal was 
performed twice per week.  
 
Drug Treatment 
 For RNA isolation experiments, a total of six confluent T-150 flasks were treated 
with peptide CMX-8933.  The peptide CMX-8933 (in 5% xylitol HBSS) was added to 
the media at a final concentration of 10 ng/ml, and the 37°C incubations continued for 5 
hours prior to  isolation of total cellular RNA.  Six untreated T-150 culture flasks were 
designated control flasks. 
 
Anoxia Experiments 
 Anoxic cultures for Western blots were provided by CereMedix, Inc.  Anoxic 
conditions (low oxygen) were induced for 24 hr in a special sealed cell culture incubator 
using a flush of N2, H2, and CO2 gases in the presence of a palladium converter to remove 
trace amounts of O2.  Following the 24 hr induction of anoxia, peptide stimulations were 
performed as described in Culture Conditions. 
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Isolation of Total Cellular RNA  
 
Total cellular RNA was isolated from murine NB2a neuroblastoma cells using the 
Clontech Atlas Pure Total RNA Labeling System (# K1038-1).   
 
Cell Collection  
 A plastic cell scraper was used to dislodge the cells from the bottom of the T-150 
culture flasks.  The cell suspension was poured into a 50ml plastic tube and centrifuged at 
2,000 rpm for 5 minutes to pellet the cells.  The supernatant was discarded leaving a 
small volume for cell transfer into one 2 ml eppendorf tube per sample.  The tubes were 
microfuged for 30 seconds to pellet the cells and to ensure complete removal of all the 
supernatant. 
 
Cell Lysis 
   A volume of 500 µl of denaturing solution was added to the cell pellet.  Cells 
were resuspended by pipetting up and down, and vortexing.  The lysate solution was 
incubated on ice for 5-10 minutes.   The solution was separated into two 2 ml eppendorf 
tubes (0.25 ml per tube).  After vortexing the solution again, the lysate was 
microcentrifuged at 12,000 rpm (Sanyo Micro Centaur) for 5 minutes at 4°C to remove 
cellular debris.  The entire supernatant was then transferred to new 2 ml centrifuge tubes 
(0.25 ml per tube). 
 
Phenol Extraction 
A volume of 0.5 ml of TE-saturated phenol was added to each tube.  The tubes 
were capped securely, vortexed vigorously, and incubated on ice for 5 minutes.  Next, 
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0.15 ml of chloroform was added per tube, and the sample was shaken and vortexed 
vigorously for 1-2 minutes.  It was then incubated on ice for another 5 minutes.  The 
organic/aqueous mixture was microcentrifuged at 12,000 rpm for 10 minutes at 4°C, and 
the upper aqueous phase containing the RNA was transferred to new 1.5 ml eppendorf 
tubes, making sure not to pipet any material from the white interphase or lower organic 
phase.    
 
Isopropanol Precipitation 
To the aqueous supernatant, a volume of 1 µl of 20 mg/ml glycogen was added 
per tube followed by the slow addition of 0.5 ml of isopropanol.  The sample was mixed, 
incubated on ice for 10 minutes, and then microcentrifuged at 12,000 rpm for 15 minutes 
at 4°C to pellet the RNA.  Supernatants were immediately removed without disturbing 
the RNA pellets. 
 
Pellet Wash 
A volume of 0.25 ml of 80% ethanol was then added per tube; the tubes were 
inverted several times, then microcentrifuged at 12,000 rpm for 5 minutes at 4°C to again 
pellet the RNA.  Immediately the supernatant was carefully discarded, and the RNA 
pellet was dried in a speed vac-apparatus for 5 minutes.   
 
Pellet Dissolution 
The pellets from both tubes were resuspended in a total of 30 µl of RNase-free 
dH2O.  The tubes were heated at 50°C for 5 minutes, occasionally flipping the tubes to 
dissolve the RNA.  In order to assess RNA yield, 1 µl of sample was added to 1 ml of 
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dH2O, and the absorbance was taken at 260 nm.  The remaining sample was aliquotted 
and stored at -80°C.  
 
Assessing the Yield and Integrity of Total RNA  
In order to assess the yield and integrity of the total RNA samples, a denaturing 
agarose gel was prepared and run.  First, a mini-gel box and combs were thoroughly 
washed with deionized water.  A 250 ml beaker containing a magnetic stir-bar was 
obtained, and 1 g of agarose was weighed and mixed with 82.5 ml of water.  The solution 
was heated in a microwave oven for 2 minutes and placed on a magnetic stir-plate to stir 
slowly for 2 minutes to cool.  While the solution was stirring, 10 ml of 10X MOPS buffer 
and 7.5 ml of formaldehyde were added.  The stirring was continued for 1 minute, and 
then the solution was poured into the gel tray.  The gel was left to solidify at room 
temperature for 1 hour, then the gel comb was removed and the gel was submerged in the 
gel box with 1X MOPS buffer.  
The RNA loading solution was prepared immediately before running the gel by 
mixing the following (for 6-10 samples): 45 µl of formaldehyde, 45 µl deionized 
formamide, 10 µl 10X MOPS buffer, 3.5 µl EtBr (10 mg/ml), 1.5 µl 0.1M EDTA (pH 
7.5), and 8 µl 10X bromophenol blue dye (in 50% glycerol).  A volume of 15 µl of RNA 
loading solution was added to 2 µg (usually 2 µl) of total RNA and mixed well.  The 
solution was heated at 70°C for 15 minutes and cooled on ice for 1 minute.  The sample 
solution was then loaded onto the gel, and electrophoresed at 50-60 V until the blue dye 
reached the midpoint of the gel tray.  RNA was visualized on a UV transilluminator.  
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cDNA Probe Synthesis for Rat Nylon Atlas Array 1.2 (catalog # 7854-1) 
 cDNA probe synthesis from total cellular RNA was performed in accordance with 
Clontech’s Atlas cDNA Expression Array User Manual (# PT3140-1). 
 
Preparation of Master Mix  
 First, a Master Mix was prepared at room temperature for all labeling reactions. 
The following reagents were combined in a 0.5 ml microcentrifuge tube at room 
temperature for each sample of RNA: 2 µl of 5X Reaction Buffer, 1 µl of 10X dNTP 
Mix, 3.5 µl of [α-32P] dATP (3,000 Ci/mmol), and 0.5 µl of DTT (100 mM).  Then, a 
PCR thermocycler was preheated to 70°C.  
 
RNA Denaturation and Primer Annealing 
 For each reaction, 3 µl total cellular RNA (2-5 µg) and 4 µl CDS Primer Mix (a 
special combination of primers designed specifically for the Atlas filter) were combined 
in a labeled 0.5 ml PCR tube.  Next, the reactions were mixed well by pipetting, and spun 
briefly in a microcentrifuge.  Then, these tubes were incubated in the PCR thermocycler 
at 70°C for 2 minutes.  After 2 minutes, the temperature of the thermocycler was reduced 
to 50°C, and the tubes were incubated for 2 more minutes.  During this incubation, 1 µl 
MMLV Reverse Transcriptase was added per reaction to the Master Mix, it was mixed by 
pipetting, and incubated at room temperature for 2 minutes.  
 
Reverse Transcription 
 After the incubation of two minutes was completed, 13.5 µl of Master Mix was 
added to each 7 µl annealed RNA sample, ensuring that the RNA samples in the 50°C 
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thermocycler were not removed for longer than was necessary to add the Master Mix. 
The contents of the tubes were mixed by pipetting and then immediately returned to the 
thermocycler.  The tubes were then incubated in the PCR thermocycler at 50°C for 25 
minutes.  After incubation, 2 µl of 10X Termination Mix was added to each tube.  The 
tubes were stored on ice until column chromatography.  
 
Column Chromatography 
 To purify the labeled cDNA from unincorporated 32P-labeled nucleotides and 
small cDNA fragments, the following procedure was performed.  Before using the Buffer 
NT3, 15 ml of 95% ethanol was added to the bottle.  First, the probe synthesis reactions 
were diluted by adding 177.5 µl of Buffer NT2.  This makes a total of 200 µl.  Second, a 
NucleoSpin Extraction Spin Column was placed into a 2 ml Collection Tube, and the 
sample was pipetted into the column.  The tube was then microcentrifuged at 14,000 rpm 
for 1 minute.  The Collection Tube and the flowthrough containing the waste were then 
discarded into the appropriate container for radioactive waste.  Then, the NucleoSpin 
column was inserted into a fresh 2 ml Collection Tube, and 400 µl of Buffer NT3 wash 
was added to the column.  The sample was microcentrifuged at 14,000 rpm for 1 minute, 
and the tube and flowthrough were discarded again.  The addition of Buffer NT3 wash 
and the centrifugation steps were repeated twice more.  The NucleoSpin column was then 
transferred into a clean 1.5 ml microcentrifuge tube, 100 µl of Elution Buffer NE was 
added, and the column was allowed to soak for 2 minutes.  The tube was 
microcentrifuged at 14,000 rpm for 1 minute to elute the purified cDNA probe.  The 
approximate radioactivity of the liquid eluted into the microcentrifuge tube versus that 
remaining in the column were assessed using a Ludlum hand-held Geiger counter to 
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monitor efficient elution from the column.  The counts should be higher in the eluate tube 
than in the column, otherwise the elution was repeated.  
 
Probe Hybridization  
 Hybridization of cDNA probe to the Rat Nylon Atlas Array filter was performed 
using Clontech’s Atlas cDNA Expression Array Protocol (# PT3140-1).  First, 5 ml of 
ExpressHyb was pre-warmed at 68°C.  Next, 50 µl (0.5 mg) of sheared salmon testes 
DNA was heated at 97°C for 5 minutes to denature the DNA, then quickly chilled on ice 
to prevent snap-back.  Then, the denatured salmon testes DNA and the 5 ml pre-warmed 
ExpressHyb aliquot were mixed, and kept at 68°C.  A Tupperware container was filled 
with deionized water and the Rat Nylon Array 1.2 (catalog #7854-1, stored at -20°C) was 
placed in the Tupperware to wet it.  All the water was then poured off and 5 ml of the 
68°C testes DNA/ExpressHyb solution was added to the membrane.  This step was 
performed quickly to ensure that the membrane would not dry.  Then, the membrane was 
prehybridized for 30 minutes with continuous agitation at 68°C in an air incubator.  Next, 
the probe was prepared for hybridization by adding 5 µl Cot-1 DNA (1 mg/ml) to the 
entire 100 µl pool of labeled probe.  The probe was then incubated in a boiling water bath 
for 2 minutes to denature it, and incubated on ice for 2 minutes.  This mixture was added 
to the prehybridization solution and membrane in the Tupperware, ensuring that the 
probe was not directly added to the membrane, and that the two solutions were 
thoroughly mixed together.  The membrane was then hybridized overnight with 
continuous agitation at 68°C.  If necessary, 2-3 ml of extra pre-warmed ExpressHyb was 
added to the solution to ensure that the entire membrane was in contact with 
hybridization solution at all times.  
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 The next day, Wash Solution 1 (2X SSC, 1% SDS) and Wash Solution 2 (0.1X 
SSC, 0.5% SDS) were pre-warmed at 68°C.  The hybridization solution was discarded in 
an appropriate radioactive waste container, and was replaced with 200 ml of pre-warmed 
Wash Solution 1.  The membrane was washed for 30 minutes with continuous agitation at 
68°C.  This process was repeated three more times.  Then, one 30-minute wash was 
performed using 200 ml of pre-warmed Wash Solution 2 with continuous agitation at 
68°C.  One final 5-minute wash was performed in 200 ml of 25°C 2X SSC with agitation 
at room temperature.  Using forceps, the membrane was removed from the container, and 
the excess Wash Solution was shaken off, never allowing the membrane to dry.  The 
membrane was immediately wrapped in a plastic bag and sealed with a bag sealer. 
Finally, the membrane was exposed to BioMax x-ray film at -80°C with an intensifying 
screen for 5 days.  When the exposure was complete, the membrane was kept wrapped in 
plastic, and stored at -20°C until stripped for re-use.   
 
Probe Removal  
To strip the cDNA probes from the membrane, 500 ml of 0.5% SDS solution was 
heated to boiling in a 2-L beaker.  Then the membrane was removed from the plastic bag, 
and placed in the boiling solution for 5-10 minutes.  The SDS solution was then removed 
from the heat and allowed to cool for 10 minutes.  The Atlas Array filter was then 
removed from the solution and immediately re-wrapped in a new plastic bag and sealed.  
To ensure the stripping procedure was effective, the membrane was checked with 
the hand-held Geiger counter, and by exposure to x-ray film for 3 days.  Once the 
efficacy of the stripping was verified, the membrane was stored at -20°C until needed.  
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Reverse Transcriptase - Polymerase Chain Reaction (RT-PCR) 
 RT-PCR was performed using Ambion’s RETROscript, First Strand Synthesis Kit 
for RT-PCR Protocol (catalog # 1710) to verify the upregulation of specific candidates 
identified from the arrays. 
 
Heat Denaturation of the RNA and Reverse Transcription  
 Each reaction was performed in a 0.5 µl eppendorf tube.  First, 2 µg of total 
cellular RNA was added to 2 µl of the antisense primer and brought up to 12 µl with 
nuclease-free dH2O.  The tubes were then mixed, spun briefly in a microcentrifuge, and 
heated for 3 minutes at 70-85°C in the thermal cycler.  The tubes were then removed to 
ice, spun briefly, and the following components were added (for each 12 µl sample to 
make a 20 µl reaction volume): 2 µl of 10X RT Buffer, 4 µl of dNTP mix, 1 µl of RNase 
Inhibitor, and 1 µl of MMLV Reverse Transcriptase.  The reaction was then mixed 
gently, spun briefly, and incubated at 42-44°C for one hour.  Upon completion of the 
reverse transcription, the reactions were then incubated at 92°C for 10 minutes to 
inactivate the reverse transcriptase.  After this point, the samples could be stored at           
-20°C, or analyzed by agarose electrophoresis.  
 
PCR  
 The following components were mixed in a separate 0.5ml tube for each PCR 
reaction, 5 µl of the RT reaction described above, 5 µl of 10X PCR buffers, 2.5 µl of 
dNTP mix, and nuclease-free dH2O to make 50 µl.  Then the following were added: 2.5 
µl of 50 µM sense primer and 0.4 µl (2 U) of thermostable Taq DNA Polymerase.  The 
samples were mixed, spun briefly and then placed in the thermal cycler for the following 
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program: 94°C for 2 minutes to initially denature the templates, then 30 cycles of the 
following three steps: 94°C denaturation for 30 seconds, 60°C annealing for 30 seconds, 
and 72°C elongation for 40 seconds.  After these 30 cycles, a final polishing extension for 
the samples was performed at 72°C for 5 minutes.  The tubes were then stored at 4°C 
until the next day or analyzed by agarose gel analysis of RT-PCR products.  
 
Analysis of RT-PCR Products  
 To analyze the RT-PCR products, 10 µl aliquots of the 50 µl reaction mixes were 
loaded onto a non-denaturing 2.5% agarose gel containing 0.5 µg/ml of ethidium bromide 
and 1X TBE.  A total of 2 µl of the high-resolution gel loading solution was mixed with 
10 µl of the RT-PCR mix and 10 µl of this mixture was loaded into the wells of the gel.  
1X TBE was used as the electrode buffer.  The marker used was λ/Pst I (10 µl of 0.2 
µg/µl stock).  The remaining RT-PCR products and the PCR reaction mixes were stored 
at -20°C.   
 
Western Blot Analysis 
 Western blots were used to analyze SOD protein levels in total cell lysates 
prepared from in vitro cultured rat primary cortical cells or from mouse brain and heart 
treated in vivo.    
 
Gel Polymerization 
 The gel was polymerized between two non-siliconized plates, one small (6-inch 
by 8-inch) back plate and one large (8-inch by 8-inch) front plate.  Two side spacers and 
a bottom spacer, all 0.8 mm thick, separated the plates.   
 33
 The lower resolving gel was prepared first by adding 7.6 ml distilled H2O, 6.7 ml 
30% Acrylamide (2.7 % cross-linking), 5.1 ml 1.5 M Resolving Gel Buffer (1.5 M 
Trizma base in distilled H2O), 200 µl 10% SDS, and 400 µl 5% Ammonium Persulfate to 
a 50 ml conical tube.  Immediately before the gel was poured, 10 µl of 100% TEMED 
was added to initiate polymerization.  The tube was gently mixed by slow inversion and 
the solution was then poured between the plates to a height approximately 1.5 cm from 
the top of the small plate.  Distilled water was used as an overlay to allow the gel to 
polymerize more evenly.  The lower gel was allowed to polymerize for at least 20 
minutes, then the water overlay was poured off. 
 The upper stacking gel was prepared by adding 5.52 ml distilled H2O, 1.67 ml 
30% Acrylamide (2.7% cross-linking), 2.5 ml 0.5 M Stacking Gel Buffer (0.5 M Trizma 
base in distilled H2O), 100 µl 10% SDS and 200 µl 5% Ammonium Persulfate to a 15 ml 
conical tube.  Immediately before pouring, 10 µl 100% TEMED was added to initiate 
polymerization.  The contents were mixed by gentle inversion and then poured above the 
lower gel.  A 20-stall comb was carefully inserted, avoiding any bubbles, to a depth of 
approximately 0.5 cm into the upper gel to create sample wells.  The stacking gel was 
allowed to polymerize for at least 20 minutes.  At this point, if the gel was to be left 
overnight, the open end was tightly wrapped in saran wrap to prevent dehydration.   
 
Gel Electrophoresis 
 Just prior to electrophoresis, the clamps holding the plates together were removed 
along with the bottom spacer, and the back plate was cleaned and dried.  The gel was 
placed in a V-16 vertical electrophoresis unit, using clamps to press the gaskets tightly 
against the upper reservoir of the unit.  The upper and lower reservoirs were filled with 
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Protein Electrode Buffer (25 mM Trizma base, 0.192 M Glycine, 0.1 % SDS) and a 
syringe was used to remove any bubbles trapped at the base of the gel between the plates.  
The comb was then removed and the wells cleaned with reservoir buffer.  Pre-
electrophoresis was performed for one hour at approximately 150 Volts.  Prior to loading, 
the protein samples were heated in a boiling water bath for 2 minutes, then microfuged 
briefly.  A V16 pipette tip was used to load the samples (usually 5 µl) into the wells of 
the gel.  Elecrophoresis was performed for approximately 3 hours or until the 
bromophenol blue dye had run about 4/5 of the way down the gel.   
 
Gel Transfer 
 After electrophoresis, the plates were removed from the V-16 unit and the side 
spacers were removed.  The plates were very gently pried apart using a pizza cutter.  
With the gel still laying on one of the plates, the original lower right corner was marked 
by cutting away the corner of the gel.    
A piece of nitrocellulose membrane (0.45 µm pore size) was cut to match the size 
of the gel.  The lower right corner of the membrane was also cut to match the gel.  The 
membrane was dipped in the pre-chilled transfer buffer (48 mM Trizma Base, 39 mM 
Glycine, 0.037% SDS, 20% methanol) and placed carefully over the gel.  Air bubbles 
were removed by smoothing a gloved finger over the membrane.  Two pieces of 3MM 
paper were then cut to match the size of the gel.  The first was dipped in transfer buffer 
and placed over the membrane.  Bubbles were again removed in the same manner as with 
the membrane.  The gel and lower plate were flipped over and the plate was removed.  A 
second piece of pre-soaked 3mm paper was placed over the gel.  Again, bubbles were 
smoothed out.  Sponges were placed on both sides of the gel/membrane/paper sandwich 
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and the plastic holders were locked into place around the sponges.  The plastic holder was 
placed into the transfer unit, with the membrane side of the sandwich facing the positive 
anode so the proteins will transfer from the gel towards the positive anode onto the 
membrane.  The transblot unit was placed in the refrigerator with the electromagnetic 
stirrer set on a low speed.  The current was set to 50 V for 2 hours at 4ºC, usually on an 
electronic timer. 
 
Membrane Blocking/Antibody Incubations 
 After gel transfer, the membrane was immediately moved to a tupperware 
container, the protein side was marked with a felt pen , and it was covered completely in 
freshly made casein blocker solution (1X PBS, 1% Casein powder, 0.2% Tween-20).  
The membrane was incubated at 25ºC on the red rocker shaker at low speed for one hour.  
The membrane was then transferred to a fresh tupperware container and submerged in 50 
ml of fresh casein blocker solution for the primary antibody incubation.  50 µl of primary 
antibody (rabbit anti-SOD, Rockland # 100-4191) was added to the blocker solution to 
make a 1:1000 dilution and the membrane was incubated at 25ºC on the red rocker shaker 
at low speed for at least two hours.  The membrane was then transferred to a fresh 
tupperware container and washed twice in PBS-Tween (1X PBS, 0.05% Tween-20) for 
five minutes each at vigorous speed on a gyratory shaker to lower the background during 
film development by removing loosely associated primary antibody. 
 The membrane was again moved to a fresh tupperware container and covered in 
approximately 50 ml blocker solution for secondary antibody incubation.  50 µl of 
secondary antibody (0.4 mg/ml Glycerol Stock of Goat Anti-Rabbit-HRP, Pierce, catalog 
# 31460) was added to the blocker solution, and the membrane was incubated at 25ºC on 
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the red rocker shaker at low speed for at least two hours.  Following secondary antibody 
incubation, the membrane was transferred to a fresh tupperware container and washed 
three times in PBS-Tween for five minutes each at vigorous speed on a gyratory shaker, 
and then briefly washed once in 1X PBS.   
 
Chemiluminescent Detection 
 During the final wash in 1X PBS, 5 ml Luminol/Enhancer Solution was mixed 
with 5 ml Stable Peroxide Solution (both solutions represent Pierce # 34080 Supersignal 
Chemiluminescent substrate for Westerns) in a 15 ml plastic tube.  The washed 
membrane was placed on a piece of foil, protein side up, and the detection mix was 
poured over the membrane.  A glass pipette was used to roll the solution evenly over the 
membrane, and it was incubated for five minutes at room temperature, rolling at one 
minute intervals to move aside oxygen bubbles caused by the HRP reaction.   
 After incubating, the corner of the membrane was dabbed on a kim-wipe to 
remove excess solution and then placed between two sheets of a clear plastic Photogene 
Development Folder (Gibco BRL # 18195-016).  The holder was placed inside a light-
tight cassette without a screen for transportation to the darkroom. 
 
X-Ray Film Development 
 Kodak X-Omat AR film was used for x-ray detection, and exposed to the 
membrane for 1-5 seconds, or until the negative control band was just visible after film 
was developed.  Signals easily observed on film after 1-5 seconds exposure were visible 
to the naked eye before developing the film.  If band hollowing occurred due to substrate 
depletion, extra substrate solution was added to the membrane.  Immediately after 
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exposure to the membrane, films were placed in GBX developer solution for 5 minutes.  
The film was dipped in a water bath briefly, and then placed in Kodak Rapid Fixer plus 
Hardener for 3 minutes with periodic agitation.  Finally the film was washed for 5 
minutes in tap water then allowed to air dry.  Bands were quantified using Scion Image 
Software (NIH).   
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RESULTS 
 
The therapeutic benefits of over-expressing the anti-oxidative enzyme SOD in 
attenuating free radical-induced oxidative damage prior to ischemic injury in transgenic 
animals is well established in the literature as mentioned in the background.  The goal of 
this project was to investigate whether EPN peptide mimetics 9236 and 8933 that are 
both known to reduce ischemic volume in rat models for stroke, increase the cellular 
levels of SOD and its mRNA.  We also wanted to investigate the pattern of SOD 
upregulation in rat cortical cultures treated with either unconjugated peptide 8933 or the 
8933-DHA conjugate.  Our final goal was to test whether anoxia or ischemic 
preconditioning includes the upregulation of SOD.  Experiments were performed using a 
mouse neuroblastoma cell line and primary rat cortical cell cultures as examples of 
transformed and primary cultures, respectively.   
 
Total Cellular RNA Isolation from Murine Neuroblastoma Cells 
Cultured mouse Nb2a neuronal cells were selected because preliminary 
experiments indicated that addition of goldfish EPN to these mouse cells induces neurite 
sprouting (Shashoua, 1991), one of the hallmarks of neurotrophic factors.  Cultures at 
90% confluency were treated with 10 µg/ml of the peptide 8933 for a period of 5 hours 
prior to total cellular RNA isolation.  Table 1 summarizes the various neuronal cell 
samples tested in this thesis and their corresponding RNA yields after the isolation 
procedure.  Because the initial experiments with single T-75 flasks yielded only about   
45 µg RNA, T-150 flasks were used for subsequent experiments (3 per sample).  
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Table 1.  Neuronal Cell Sample Size and Corresponding RNA Yields 
 
Date Sample 
Size of culture 
flask 
No. of culture 
flasks 
RNA 
yield µg 
Conc. 
µg/µl 
05-04-02 Control T-75 1 45.6 0.45 
05-04-02 8933-treated T-75 1 43 0.43 
09-20-02 Control (Set A) T-150 3 421.2 14.04 
09-20-02 8933-treated (Set A) T-150 3 440.4 14.68 
09-20-02 Control (Set B) T-150 3 417.6 13.92 
09-20-02 8933-treated (Set B) T-150 3 428.4 14.28 
 
 In order to verify that the RNA samples were intact following the RNA isolation 
protocol, denaturing formaldehyde agarose gel electrophoresis was performed.  Discrete 
28S and 18S ribosomal RNA bands were used as evidence of intact RNA.  Figure 9 
displays an example of an RNA integrity gel for Set A and Set B.  The 28S and 18S 
ribosomal RNA bands at 4.5 kbp and 1.9 kbp respectively can clearly be seen in each 
sample indicating that the RNA isolated was intact. 
 
 
Fig 9. RNA Integrity Gel.  Analysis of total cellular RNA isolated from Nb2a cells. 
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Multiple Gene Profiling Using Rat Nylon Arrays 
 Clontech’s Atlas Nylon cDNA expression arrays are densely packed with sample 
dots of known cDNA sequences spotted on positively charged nylon membrane.  Plasmid 
and bacteriophage DNAs are included as negative controls to confirm hybridization 
specificity, along with several housekeeping cDNAs as positive controls for normalizing 
mRNA abundance (Clontech User Manual).  We selected Rat Nylon Atlas Array 1.2 
(catalog # 7854-1) because it provided a total of 1,176 rat genes, which play a key role in 
a variety of different biological processes.  Radiolabeled cDNA was synthesized from 
RNA isolated from primary rat cortical cultures treated for 3 hours with 5 ng/ml of the 
peptide 8933 and from untreated cultures.  The radiolabeled samples were hybridized to 
duplicate array filters.   Figure 10 shows the side-by-side comparison of the expression 
profiles of RNA isolated from untreated (upper panel) and 8933-treated (lower panel) 
samples.  Equal signals were observed for all the true housekeepers (β-actin, 
polyubiquitin, GAPDH and S29 Ribosomal protein).  Because of the high cost associated 
with these rat nylon arrays ($1,400), I was unable to perform additional independent 
observations, so used this single array experiment specifically as a “Hypothesis 
Generator” for my thesis to identify candidates worth further experimentation.      
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Fig 10. Rat Nylon cDNA Expression Array Used as a ‘Hypothesis Generator’.  The arrays were 
exposed for 5 days at –80oC.  A grid provided with the kit was used to identify specific mRNAs 
upregulated.  The 5 dots on the lower right corner in both the membranes represent the housekeeper with 
equalized signal intensity.  The 8933-treated nylon membrane (lower panel) shows upregulation of 
numerous candidates indicated by strong darker dots compared to the untreated (upper panel).    
 
Array Summary 
The signal intensities for some specific interesting candidates have been 
summarized according to their biological function in Table 2.  The symbol +++ (or more) 
signifies a strong signal (dark dots on the membrane), ++ signifies a moderate signal 
(medium dots), + signifies a low signal (light dots) and 0 signifies no observable signal.  
For both the membranes the positive controls (second group in the table) showed a 
positive signal, the negative controls (first group in the table) showed no signal and the 
housekeepers (third group in the table) had equal signals.   
           Rat Nylon Array Assay 05-18-02
          5-Day Exposure 
 Control 
8933-Treated
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The most exciting candidate of direct interest to this thesis was the anti-oxidative 
enzyme SOD (fourth group in the table).  It showed at least three times higher signal in 
the drug treated sample compared to the control.  Three calcium-binding proteins (fifth 
group in the table), which could theoretically mediate ischemic damage by counteracting 
calcium accumulation, were also upregulated following drug treatment.  In addition, other 
groups of gene involved in stress response, protease inhibition, energy metabolism and 
translation were also upregulated in the 8933-treated sample.  Many scientists worry that 
since we are stimulating neuronal cell division with NTF therapy, we may induce cancer 
in these cells.  However this array data showed no upregulation of any of the seven 
oncogenes tested (one above the last group in table).  In fact, one metastasis inhibitor 
factor was upregulated.  
 
Table 2. Summary of Hybridization Array Data   
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Table 2, continued 
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Table 2, continued 
 
  
CMX-8933 Increases the Titer of SOD mRNA in Nb2a Cells 
 During array analysis, because of variations inherent in any hybridization 
reaction, a further confirmation using Reverse Transcriptase-Polymerase Chain Reaction 
(RT-PCR) is always recommended.  I chose the potentially upregulated anti-oxidative 
enzyme SOD for further analysis by RT-PCR because of its known function in assuaging 
ischemic damage.  Figure 11 shows the RT-PCR result for SOD performed in triplicate.   
As predicted, the levels of the housekeeper Polyubiqutin (amplicon size 231 bp) were 
equal between treated and untreated samples, but SOD mRNA (amplicon size 265 bp) 
was highly elevated in the CMX-8933 treated cells. 
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Fig 11.  CMX-8933 Elevates SOD mRNA Levels in Nb2a Cells.  Polyubiquitin (amplicon size 231 bp) 
was used as housekeeper.  The results of 3 independent trials indicate that the SOD bands (amplicon size 
265 bp) were stronger in samples treated with 10 ng/ml of CMX-8933 for 5 hours and hence this data 
correlates well with the results obtained from the hybridization array.     
 
The means +/- standard deviation for the SOD RT-PCR experiment are shown in 
figure 12.  The histobars illustrate the mean fold increase in a triplicate determination. 
The figure shows a 6.5 fold average increase in SOD mRNA levels for the 8933 treated 
samples compared to the control.  Error bars denote sample variation within the triplicate 
set.  A statistical analysis was performed using the Analysis of Variance (ANOVA) test.  
It indicated that the SOD upregulation was significant (p = 0.001). 
            
                                  *: p=0.001  
 
Fig 12.  Quantitation Data for SOD RT-PCR.  Histobars indicate means for 3 trials.  Error bars denote 
standard deviations in a triplicate set.  Asterisks denote the two histobars compared for the p value. 
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CMX-8933 and CMX-9236 Increase the Cellular Titers of SOD Protein   
 Western blots were used to determine whether SOD protein also increases like its 
mRNA when treated with EPN peptide mimetics.  Five different SOD Western 
experiments were performed using whole cell lysates prepared from either in vitro 
cultured rat primary cortical cells or from mouse brain and heart treated with 8933 via i.v. 
administration in vivo.  The SOD protein levels were compared to that of vehicle-treated 
control groups to determine effectiveness of treatments.  
 
In Vitro Dose-Response Experiment 
To analyze the effect of 8933 and 9236 on SOD levels at increasing doses of the 
peptides, rat primary cortical cultures were pre-incubated with 1, 10 and 100 ng/ml of 
either peptide for a period of 5 hours.  Figure 13 shows the results for this in vitro dose-
response experiment.  A dose of 10 ng/ml showed the darkest SOD band at the expected 
size of SOD protein (34 kDa).  Hence a dose of 10 ng/ml may be the optimal dose for 
these Nb2a cultures.  A further increment of dose to 100 ng/ml did not show a further 
increase in SOD levels, indicating a possible post-saturation effect of the putative peptide 
receptors.  The bands were quantified using Scionimage Software.  Histobars shown 
below each panel indicate mean signal intensity.  The results of four additional 
independent experiments (panel B) correlate nicely with test 1. 
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Fig 13. Peptides 8933 and 9236 Increase SOD Levels in a Rat Primary Cortical Cells in a Dose-
Dependant Manner.  Panel A represents the Test-1 western blot for CMX-8933 and CMX-9236.  Peptide 
stimulations were carried out for 5 hours.  Panel B shows the results of four additional sets of the same 
experiments.  Arrows on the right denote the positions of 34 kDa SOD-1.  Arrows on the left denote the 
positions of biotinylated markers.  Histobars represent the signal strength quantitated using Scion image.  
B
A 
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The means of trials 1 through 5 for the in vitro dose response experiment are 
shown in figure 14.  The figure shows that both peptides 8933 and 9236, at an optimal 
dose of 10 ng/ml, cause an average increase of 8.5 fold in SOD levels over the vehicle-
treated controls with a significant p value (p < 0.001).   
 
 
                     
              Fig 14. Statistical Analysis of Five In Vitro Dose-Response Experiments. 
Error bars denote standard deviations.  Asterisks denote p values on selected  
sample pairs. 
 
  
In Vitro Time-Course Experiment 
 To determine the optimal time period at which the SOD response occurs   
following treatment of rat cortical cultures with therapy peptides 8933 and 9236, a time-
course experiment was performed.  Figure 15 shows the result of an in vitro time-course 
experiment wherein rat primary cortical cultures were treated with 100 ng/ml of peptide 
8933 or 9236 for a period of 1, 5 and 24 hours.  A maximal increase in SOD levels was 
observed at 5 hour peptide treatment indicating the optimal time point.  A prolonged 
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treatment for 24 hours did not further increase the SOD levels, again indicating a post-
saturation effect.  Figure 15 B shows the results of two additional independent trials with 
an identical pattern of SOD upregulation, thus confirming reproducibility of the data. 
 
             
          
      
 
 
 
 
 
 
 
 
 
 
  
        
              Fig 15. Time-Course of Rat Cortical Cultures Treated with Peptide 
8933 or 9236 Show Maximum SOD Elevation at 5 Hours.  Panel A  
represents Test-1 western blot for CMX-8933 and CMX-9236 at 100 ng/ ml.  
 Panel B shows the results of two additional independent trials.    
 A 
B 
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The means of test 1 through 3 for the in vitro time-course experiment are shown 
in figure 16.  The figure shows that both peptides 8933 and 9236 increased SOD levels   
compared to the vehicle-treated control optimally at the 5 hour time point with average 
increases of 10 fold and 8.5 fold for CMX-8933 and CMX-9236, respectively (p < 0.001 
in each case).  
                                  
                           
                           Fig 16. Statistical Analysis of Three In Vitro Time-Course Experiments. 
 
Mouse, In Vivo Dose-Response Experiment 
  Our next goal was to perform a mouse, in vivo dose response experiment to 
investigate if there were any changes in SOD protein levels in the brain and heart of mice 
treated i.v. with the therapy peptide.  Mice were treated for five hours with either 1 or 6 
mg/kg of peptide 8933.  Total cellular proteins were then isolated from brain and heart 
post-treatment and examined for SOD upregulation using western blots.  Figure 17 shows 
a dose-dependent upregulation of SOD levels in both the brain and heart of mice.  The 
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results were reproduced in four separate experiments (fig 17B), each of which is 
consistent with the data shown in fig 17A.   
 
 
Fig 17.  CMX-8933 Elevates SOD Levels in the Brain and Heart of a Mouse.  Mice were injected i.v. 
with various doses of peptide, then sacrificed 5 hours later.  Total cellular proteins isolated from mouse 
brain and heart post-peptide treatment were analyzed using immunoblots.  Panel A shows SOD elevation in 
a dose-dependent manner in each organ.  Panel B shows the results of four additional independent trials.    
A 
B
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The means of trials 1 through 5 for the mouse in vivo dose response experiment 
are shown in figure 18.  The figure shows a 4 fold elevation in SOD levels in both the 
brain and heart at a 1 mg/kg dose of peptide CMX-8933 compared to untreated controls.  
The highest dose given, 6 mg/kg, increased SOD levels an average of 10 fold in the brain 
and 8 fold in the heart (p < 0.001 in each case).  
          
      Fig 18. Statistical Analysis of Five Mouse, In Vivo Dose Response Experiments.  
  
8933-DHA-BBB Conjugate Can Further Increase the Expression of SOD 
 Since previous data indicated that BBB carrier DHA could facilitate the delivery 
of dopamine to the brain (Shashoua and Hesse, 1996), we wanted to examine if the DHA 
carrier had any potential effect on the ability of 8933 to increase SOD levels.  To analyze 
this, rats were injected i.v. with 1 mg/kg of DHA-8933 (peptide 8933 coupled to a DHA 
carrier) or unconjugated 8933 for a period of 5 hours.  Figure 19 clearly indicates that, 
following systemic administration, the DHA-8933 conjugate is capable of further 
increasing the SOD titers in rat brain compared to the unconjugated peptide.   
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Fig 19.  The 8933-DHA Conjugate Shows Further Increased SOD Expression Compared to  
Unconjugated 8933.   Mice were injected i.v. with 1 mg/kg peptide (on vehicle control) and animals  
were sacrificed 5 hours later.  Western blot analysis was performed using total cellular proteins isolated 
from peptide treated rat brains.  The experiment was performed with duplication of doses.  Panel B shows 
the results of three additional trials with similar observations.
  
A
B
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The means of trials 1 through 4 for the in vivo carrier experiment are shown in 
figure 20.  The uncoupled peptide 8933 at a dose of 1 mg/kg alone causes an average 5 
fold increase in SOD levels compared to the vehicle-treated control (p=0.001).  However 
coupling the peptide 8933 to DHA can bring about a further 2.4 fold increase (12 fold 
overall) in SOD levels at the same dose compared to the uncoupled 8933 (p<0.0001).         
 
       Fig 20. Statistical Analysis of Four Carrier vs Non-Carrier Experiments. 
 
 
CMX-8933 Can Increase SOD Levels Beyond Normal Anoxic SOD Levels 
 Special cell culture incubators have recently been used as in vitro models for 
ischemia.  We tested whether peptide therapy worked in this “in vitro” stroke system.    
Rat primary cortical cultures were conditioned in an anoxic environment by 
preincubating the cultures for a period of 24 hours in an environment of N2, H2, and CO2 
gases followed by reoxygenation.  Peptide stimulation was then performed for 5 hours.  
The results of SOD Western blots performed on cells grown in anoxic conditions and 
treated with different doses of peptides 8933 and 2115 (8933 + two more N-terminal aa) 
are shown in figure 21.  Lane 1 represents culture grown under normal oxygen conditions 
used as a negative control.  SOD band in untreated anoxic cultures (lane 2) shows a 2.5 
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fold increase compared to the normoxic cultures (lane 1). This data directly indicates that 
anoxic cultures may have an inherent defense mechanism by which they upregulate SOD 
(and potentially other anti-oxidative enzymes) when placed in an anoxic environment.  
Both therapeutic peptides CMX-8933 and CMX-2115 also upregulate SOD levels in a 
dose dependent manner beyond the levels caused by anoxia alone (approx 8 fold totally).   
                               
       
Fig 21.  Western Blot Analysis Using Anoxic Neuroblastoma Cells Treated with Therapy Peptides 
8933 and 2115.  Anoxic untreated cultures (lane 2) shows SOD upregulation in contrast to normoxic 
untreated cultures (lane 1).  SOD levels are elevated in a dose-dependent manner by 5 hours of peptide 
therapy.  Panel B shows results of 2 additional trials. 
A
B
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The means of trials 1 through 3 for the anoxia experiment are shown in figure 22.  
The figure shows that anoxia alone (lane 2) causes an average 3 fold increase in SOD 
levels over the negative control grown under normal oxygen conditions (lane 1) (p= 
0.003). A dose of 1 ng/ml of peptide 8933 caused a further 2.5 fold increase in SOD 
levels (8.5 fold totally) compared to untreated anoxic cultures (lane 2) (p<0.001).  Peptide 
2115 at the same 1 ng/ml dose (lane 5) caused an overall 7.5 fold increase in SOD levels 
compared to the negative control.  A post-saturation effect was observed as the dose of 
peptide 2115 was doubled to 2 ng/ml (lane 6).   
 
                  
         Fig 22. Statistical Analysis  of Three Anoxia Experiments. 
 
 
EPN Sequences, Both Left and Right of 8933 Fail to Upregulate SOD 
 CMX-8933, an 8 amino acid peptide, is a proteolytic cleavage product of 
ependymin and exists naturally in the cerebrospinal fluid.  We wanted to examine if other 
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8 amino acid sequences present in goldfish ependymin also behave like 8933 to 
upregulate SOD.  We chose negative peptides which were 8 amino acids left or right of 
the 8933 consensus sequence.  Figure 23 shows the result of the negative peptide western 
experiment performed on rat primary cortical cultures to analyze SOD upregulation.  As 
expected, a 5 hour stimulation with peptides 8 aa left of 8933, or 8 aa right of 8933, at 
any dose tested (including 10 fold higher than tested with 8933) failed to produce any 
detectable elevation in SOD levels.  Hence it is likely that only specific portions of EPN 
(such as 8933) actually bind the putative receptor to induce signal transduction.      
  
 
Fig 23.  Western Blot Analysis Using Primary Rat Cortical   
Cultures Treated with Negative EPN Peptides.   Lane M 
represents the SOD marker as a positive control (8933 10 ng/ml).   
The negative peptides failed to increase SOD signals.  
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In summary, the data shows that 1) treatment of primary rat cortical cultures with 
goldfish peptides 8933 and 9236, representing a portion of the EPN sequence increases 
the cellular titers of SOD mRNA and SOD protein;  2) Coupling 8933 to DHA BBB-
carrier further increases SOD expression in the brain compared to 8933 alone;   3) anoxia 
induced in vitro by oxygen deprivation shows SOD upregulation as part of the cell’s 
natural response to anoxia;  4) treatment of anoxic Nb2a cells with 8933 further increases 
SOD levels compared to the levels for anoxia alone. 
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DISCUSSION 
 The data from this study demonstrate that EPN peptide mimetics CMX-8933 and 
CMX-9236 that are therapeutic in a rat stroke model are also capable of upregulating the       
antioxidative enzyme SOD.  This conclusion is based on three independent criteria; 
Treatment of primary rat cortical cultures with CMX-8933 or CMX-9236 increased SOD 
protein levels in 1) in vitro dose-dependent and time-course studies; 2) in vivo rat brain 
and heart; 3) an in vitro axoxic neuroblastoma model as a further stimulant to ischemic 
pre-conditioning.  In addition the data from this thesis demonstrates that i.v. 
administration peptides conjugated to DHA, a blood-brain barrier carrier, further elevates 
the expression of brain SOD.  Stimulation of anoxic cultures with CMX-8933 elevated 
SOD levels beyond natural anoxic levels.  These latter experiments were not performed 
with CMX-9236.  
 Superoxide dismutase, Catalase and GPX are three important enzymes 
utilized by cells to keep oxidative stress at ‘safe’ levels. Because SOD converts 
superoxide (or reactive oxygen species, ROS) to hydrogen peroxide (also a toxic ROS 
precursor), it is important that either catalase or GPX which reduce hydrogen peroxide to 
water and oxygen, are also upregulated or remain highly active to accommodate the 
increased H2O2 production from SOD.  Previous experiments in our lab have shown 
elevated catalase and GPX levels in neuroblastoma cells when stimulated with other EPN 
peptide mimetics (Armistead, 2001).  However SOD is of utmost importance since it is 
directly involved with reducing oxidative stress and hence this project focused 
predominantly on SOD.  The in vitro time and dose-response data show an average of 8.5 
fold increase in SOD levels after 10 ng/ ml peptide treatment for 12 hours over the 
vehicle-treated controls with a significant p value.  Higher doses of the peptide or longer 
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duration of peptide treatment did not further elevate the SOD levels indicating a possible 
post-saturation effect of the putative EPN receptors.  The mouse in vivo dose response 
experiment also showed that peptide CMX-8933 is indeed effective in a whole animal.  A 
dose-dependent increase in SOD was observed in both the brain and heart, with a dose of 
6 mg/kg of CMX-8933 raising levels an average of 10 fold in the brain, and 8 fold in the 
heart.  This analysis was not performed with CMX-9236.  RT-PCR analysis to assess 
SOD mRNA elevation in addition to SOD protein level also gave fruitful results, with a 
6.5 fold elevation in SOD mRNA level observed at a dose of 10 ng/ ml CMX-8933 for 5 
hours.  Altogether these data demonstrate SOD upregulation following EPN peptide 
treatment in in vivo and in vitro model systems. 
Preliminary studies in a large number of laboratories have shown that SOD plays 
a major role in neuronal protection after a focal ischemic insult.   Studies have shown that 
ischemic infarct is significantly increased in mice that lack the SOD gene (Mikawa et al., 
1995).  A variety of studies have revealed that transgenics over-expressing SOD appear 
to build resistance to cerebral ischemia (Chan et al., 1998; Sheng et al., 1999; Li et al., 
2001).  However reports of the effect of cerebral ischemia on SOD expression and 
activity in vivo are contradictory.  One study conducted to measure SOD activity in the 
serum of patients with acute ischemic stroke observed a decreased SOD activity within 24 
hours after the onset of symptoms (Spranger et al., 1997).  Therefore, it seems likely that 
antioxidants are depleted as a consequence of an excessive production of oxygen free 
radicals very early after the ischemic insult, and hence supplementation with endogenous 
SOD may be beneficial.  Because SOD is upregulated by our peptides, we predict that 
oxyradicals and oxidative stress are reduced.  Although some cells may use oxyradicals 
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as signaling molecules (like heart cells), elevation of SOD levels does not appear to 
damage such cells in transgenic animals expressing SOD in all tissues.   
I next addressed the issue of using DHA as a brain delivery vehicle for these EPN 
peptides.  DHA is an abundant fatty acid in synaptic endings (Sun and Yau, 1976), and 
hence it is rightly termed a ‘naturally occurring carrier’.  DHA also facilitates rapid 
transport of dopamine into the brain (Shashoua and Hesse, 1996).  The data from this 
thesis reveal that rats treated in vivo with 8933-DHA-conjugate doubled the SOD 
expression in the brain compared to the same dose of uncoupled 8933.  This finding is in 
agreement with previous research wherein coupling DHA to dopamine increased the 
brain uptake of dopamine by over 10-fold (Shashoua and Hesse, 1996).  Moreover 
Protarga, Inc. uses DHA with a variety of therapeutic drugs (currently in clinical trials). 
DHA by itself has no effects on AP-1 signaling (Shashoua et al., 2001), however the 
potential effects of DHA on SOD were not analyzed in this thesis.  Some researchers 
believe that administration of neurotrophic factors intravenously would allow for 
widespread distribution of the drug throughout brain parenchyma even without using 
BBB carriers (Zhang and Padridge, 2000).  However specific brain uptake of full length 
NTFs has not yet been demonstrated.  One strategy for obtaining neuroprotective effects 
in brain following the noninvasive (intravenous) targeting of NTFs is the chimeric 
peptide technology (Padridge, 1997).  
Recent studies have emerged with a new in vitro model for stroke.  This model 
uses an induced ischemic environment in vitro in a special cell culture incubator.  Anoxia 
experiments were designed to model in vitro the effects of a naturally occurring stroke.  
My western anoxia experiments strongly reveal that untreated anoxic cultures show a 3 
fold SOD upregulation compared to the normoxic untreated cultures, thus indicating that 
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these rat primary cells have an inherent mechanism by which they increase SOD levels 
when placed in a low oxygen environment.  This is particularly interesting because even 
without NTF treatment, rat neurons appear to naturally possess a mechanism for up-
regulating a protective enzyme that reduces free radicals levels following a stroke.  This 
finding extends and solidifies earlier findings in turtles exposed to an anoxic environment 
in which SOD and catalase levels dramatically increased (Willmore and Storey, 1997).  
However, no one to date has studied SOD upregulation in anoxic mammals and hence 
this present study done on rat primary cultures is the first of its kind.  Cells grown under 
anoxic conditions then treated with either peptide CMX-8933 or CMX-2115 (CMX-8933 
plus two extra amino acids) showed an additional 2.5 fold increase in SOD levels.  
Although many researchers have tried to elucidate the molecular pathways involved in 
mediating the adaptive response to oxygen deprivation, the precise mechanism of the 
resulting ischemic tolerance in stroke therapy remains a mystery.   
A good future experiment for measuring the SOD’s anti-oxidative activity would 
be the TBARS (thiobarbituric acid reactive substances) assay.  This dye measures the 
overall oxidative stress on a cell lysate.  Anoxic cultures are already subjected to 
oxidative stress and hence should contain a mixture of TBARS reactive lipid 
hydroperoxidase and aldehydes.  Treatment of these cultures using EPN peptides shown 
here to elevate SOD levels should lower TBARS reactivity.  This sensitive assay allows 
for screening and monitoring lipid peroxidation, and a direct measurement of the anti-
oxidative activity of EPN peptides by fluorometry or spectophotometry.     
Previous work has provided evidence that CMX-8933 and CMX-9236 promote 
activation of transcription factor AP-1 (Shashoua et al., 2001; Adams et al., 2003).  
These studies demonstrate that these small peptides can have properties similar to those 
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of large protein neurotrophic factors such as BDNF and NGF, which also stimulate 
neuronal growth via the activation of AP-1 (Gaiddon et al., 1996; Tong and Perez-Polo, 
1996).    Because goldfish EPN is difficult to isolate free from contaminating NGF, the 
study to prove that full-length EPN activates AP-1 is in progress.  Inhibition experiments 
performed in our lab have shown that AP-1 is activated via the mitogen-activated protein 
kinase (MAPK) pathway (Hasson, 1998; Adams et al., 2003).  Based on these known 
findings, and analogies to findings in other systems, we proposed a working hypothesis 
for these peptides.  CMX-8933 representing a naturally cleaved product of EPN, exists 
extra-cellularly, and may interact with a cell surface receptor that initiates a cascade of 
biochemical steps leading to AP-1 activation and SOD upregulation.  In contrast during 
therapeutic administration of DHA-8933 these peptides exert their biological effects not 
only by interacting with presumed EPN receptors, but also by direct delivery through the 
cell membrane via the DHA carrier.  In this latter case, it could chelate excitotoxic 
calcium rather than interact with EPN receptor.  However a detailed analysis of the 
precise pathways and genes activated by EPN will aid our understanding of its 
mechanism.   
The study presented here provides solid evidence for SOD upregulation in 
neuronal cells by EPN peptides CMX-8933 and CMX-9236.  However the negative 
peptide experiment performed in this study showed that peptides 8 aa left of 8933 and 8 
aa right of 8933 do not show significant SOD upregulation at doses 10-fold higher than 
optimal 8933 doses, hence it is likely that only specific portions of EPN (such as 8933) 
actually bind the putative receptor to induce signal transduction.  Thus future analysis for 
SOD upregulation using the full-length ependymin molecule needs to be tested.   
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Since SOD upregulation by itself is not enough to alleviate destructive neuronal 
cell death following stroke, more light should be thrown on various other proteins/genes 
also upregulated by these peptides.  The rat nylon hybridization array data generated an 
interesting expression profile with a large category of genes, each playing different roles 
in many biological processes.  The fact that calcium-binding proteins like calmodulin, 
calphobindin etc. were upregulated in the array data indicates a possible role of CMX-
8933 in counteracting calcium accumulation following stroke.  However analysis by RT-
PCR to confirm this upregulation did not give positive results, and produced bands of 
equal intensity for the control and drug treated.  One reason for this failure could be that 
we used rat nylon arrays hybridized to rat primary cortical cell cDNAs, but performed 
RT-PCR with RNA isolated from murine neuroblastoma cells using mouse primers.  
Hence the RT-PCR could be repeated in rats.  The other reason for this disconnect with 
the array data for calcium-binding proteins could be the obvious variations encountered 
in array data.  Additional repeated array experiments to confirm reproducibilty could 
have helped us build a strong case, but the high costs restricted us to just one trial.   
Immunoblots using calmodulin antibody (purchased from Zymed) to analyze calmodulin 
protein upregulation by EPN peptides in primary rat cortical cultures failed to produce 
any bands.  We learned after consultation with some western experts that calmodulin, a 
low abundance protein is very difficult to visualize using any calmodulin antibody.  
In conclusion, the data in this thesis are consistent with the proposed role of EPN 
peptides CMX-8933 and CMX-9236 in increasing the cellular titers of the antioxidative 
enzyme SOD, and thus hold potential as a future treatment in the battle to reduce brain 
damage induced by stroke.  Research will continue to investigate the possibility of newer 
and more effective neurotrophic peptides derived from goldfish ependymin. 
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